Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions

Abstract Background aims The use of allogeneic mesenchymal stem cells (MSC) to treat acute equine lesions would greatly expand equine cellular therapy options; however, the safety and antigenicity of these cells have not been well-studied. We hypothesized that equine allogeneic umbilical cord tissue...

Full description

Saved in:
Bibliographic Details
Published in:Cytotherapy (Oxford, England) England), 2011-11, Vol.13 (10), p.1180-1192
Main Authors: Carrade, Danielle D, Affolter, Verena K, Outerbridge, Catherine A, Watson, Johanna L, Galuppo, Larry D, Buerchler, Sabine, Kumar, Vijay, Walker, Naomi J, Borjesson, Dori L
Format: Article
Language:English
Subjects:
Advanced Basic Science
Animals
Cell Proliferation
equine
Horses
Hypersensitivity, Delayed - etiology
Hypersensitivity, Delayed - prevention & control
Hypersensitivity, Immediate - etiology
Hypersensitivity, Immediate - prevention & control
immune response
intradermal injection
Lymphocyte Activation - immunology
Lymphocyte Culture Test, Mixed
Mesenchymal Stem Cell Transplantation
mesenchymal stem cells
Mesenchymal Stromal Cells - cytology
Mesenchymal Stromal Cells - immunology
Mesenchymal Stromal Cells - metabolism
Other
Postoperative Complications
T-Lymphocytes - immunology
Umbilical Cord - cytology
umbilical cord tissue
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background aims The use of allogeneic mesenchymal stem cells (MSC) to treat acute equine lesions would greatly expand equine cellular therapy options; however, the safety and antigenicity of these cells have not been well-studied. We hypothesized that equine allogeneic umbilical cord tissue (UCT)-derived MSC would not elicit acute graft rejection or a delayed-type hypersensitivity response when injected intradermally. Methods Six Quarterhorse yearlings received 12 intradermal injections (autologous MSC, allogeneic MSC, positive control and negative control, in triplicate) followed by the same series of 12 injections, 3–4 weeks later, at another site. Wheals were measured and palpated at 0.25, 4, 24, 48, 72 h and 7 days post-injection. Biopsies were obtained at 48 and 72 h and 7 days post-injection. Mixed leukocyte reactions were performed 1 week prior to the first injections and 3 weeks after the second injections. Results There were no adverse local or systemic responses to two intradermal injections of allogeneic MSC. MSC injection resulted in minor wheal formation, characterized by mild dermatitis, dermal edema and endothelial hyperplasia, that fully resolved by 48–72 h. No differences were noted between allogeneic and autologous MSC. The second injection of MSC did not elicit more significant physical or histomorphologic alterations compared with the first MSC injection. Neither allogeneic nor autologous UCT-derived MSC stimulated or suppressed baseline T-cell proliferation in vitro prior to or after two MSC administrations. Conclusions Equine allogeneic UCT MSC may be safely administered intradermally on multiple occasions without eliciting a measurable cellular immune response.
ISSN:1465-3249
1477-2566
DOI:10.3109/14653249.2011.602338